Acurx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Acurx Pharmaceuticals, Inc. (ACXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 120.85 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was -641.73K shares, a 1169.54% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 675.50K shares, a 19.10% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 33.77K shares, a 96.23% decline from fiscal 2024.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 895.00K shares, a 72.95% increase from fiscal 2023.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 517.50K shares, a 370.45% increase from fiscal 2022.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 110.00K shares, a 95.33% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 120.85K shares 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-12 | -641.73K shares derived: sum of 3 quarters · filed 2026-03-12 | 33.77K shares 10-K · filed 2026-03-12 | |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -641.73K shares derived: sum of 2 quarters · filed 2025-11-12 | 33.77K shares 10-Q · filed 2025-11-12 | 33.77K shares derived: sum of 4 quarters · filed 2025-11-12 | |
| 2025-06-30 | -641.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 33.77K shares 10-Q · filed 2025-08-11 | 33.77K shares derived: sum of 3 quarters · filed 2025-08-11 | 33.77K shares derived: sum of 4 quarters · filed 2025-08-11 | |
| 2025-03-31 | 675.50K shares 10-Q · filed 2025-05-12 | 675.50K shares derived: sum of 2 quarters · filed 2025-05-12 | 675.50K shares derived: sum of 3 quarters · filed 2025-05-12 | 735.50K shares derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-17 | 60.00K shares derived: sum of 3 quarters · filed 2025-03-17 | 895.00K shares 10-K · filed 2025-03-17 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 60.00K shares derived: sum of 2 quarters · filed 2024-11-12 | 895.00K shares 10-Q · filed 2024-11-12 | 895.00K shares derived: sum of 4 quarters · filed 2024-11-12 | |
| 2024-06-30 | 60.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 895.00K shares 10-Q · filed 2024-08-08 | 895.00K shares derived: sum of 3 quarters · filed 2024-08-08 | 895.00K shares derived: sum of 4 quarters · filed 2024-08-08 | |
| 2024-03-31 | 835.00K shares 10-Q · filed 2024-05-14 | 835.00K shares derived: sum of 2 quarters · filed 2024-05-14 | 835.00K shares derived: sum of 3 quarters · filed 2024-05-14 | 885.00K shares derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-15 | 50.00K shares derived: sum of 3 quarters · filed 2024-03-15 | 517.50K shares 10-K · filed 2024-03-15 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 50.00K shares derived: sum of 2 quarters · filed 2023-11-13 | 517.50K shares 10-Q · filed 2023-11-13 | 517.50K shares derived: sum of 4 quarters · filed 2023-11-13 | |
| 2023-06-30 | 50.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 517.50K shares 10-Q · filed 2023-08-11 | 517.50K shares derived: sum of 3 quarters · filed 2023-08-11 | 517.50K shares derived: sum of 4 quarters · filed 2023-08-11 | |
| 2023-03-31 | 467.50K shares 10-Q · filed 2023-05-12 | 467.50K shares derived: sum of 2 quarters · filed 2023-05-12 | 467.50K shares derived: sum of 3 quarters · filed 2023-05-12 | 497.50K shares derived: sum of 4 quarters · filed 2023-05-12 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-15 | 30.00K shares derived: sum of 3 quarters · filed 2023-03-15 | 110.00K shares 10-K · filed 2023-03-15 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 30.00K shares derived: sum of 2 quarters · filed 2022-11-10 | 110.00K shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 30.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 110.00K shares 10-Q · filed 2022-08-12 | |||
| 2022-03-31 | 80.00K shares 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | 2.36M shares 10-K · filed 2022-03-16 | ||||
| 2021-09-30 | 2.36M shares 10-Q · filed 2021-11-12 | 3.17M shares derived: sum of 2 quarters · filed 2021-11-12 | |||
| 2021-07-31 | 100.00K shares 10-Q · filed 2022-08-12 | ||||
| 2021-06-30 | 770.00K shares 10-K · filed 2023-03-15 | 807.50K shares 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |